

Title

Dermatology Hidradenitis Suppurativa Drugs

Reference Number: FOI RDF1634

Date of Response: 07/07/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

I am writing to request information regarding the treatment of Hidradenitis Suppurativa. Please see the question below:

Q. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS), with each of the following biologic drugs:

Biologic Drug	Total
Adalimumab (Humira)	5
Adalimumab (Biosimilar)	50
Bimekizumab	0
Infliximab (Remicade)	0
Infliximab Biosimilar	0
Secukinumab	0
Ustekinumab	0